our research collaboration with Merck has produced several antibody candidates to undisclosed targets. Merck is expected to decide which of these antibody candidates, if any, they will pursue into clinical development.
"WILL" not started yet, too much stupidity going on, I thought, HERP V should work with our newly biologic components
Agree, but Stein must found something and believe that he can prove something, my guess, he is trying to validate quickly toxicity / safety of it, and we can start PII on bettr candidate to prove efficacy.
And if that happens with good success news, even 10% it will be game changer, we will have big and we may solve many cancers.